Ardelyx reported a net product sales for IBSRELA of $1.6 million, collaboration revenue of $1.0 million, research and development expenses of $9.7 million, selling, general and administrative expenses of $18.9 million, and a net loss of $26.9 million for the second quarter ended June 30, 2022.
Net product sales for IBSRELA were $1.6 million during the quarter ended June 30, 2022.
Collaboration revenue was $1.0 million for the quarter ended June 30, 2022.
Research and development expenses decreased by 62.6% to $9.7 million for the quarter ended June 30, 2022.
Net loss for the quarter ended June 30, 2022 was $26.9 million, or $0.19 per share.
Analyze how earnings announcements historically affect stock price performance